SCHEMBL6489328

SCHEMBL6489328

Cc1ccc(-c2cc(C)ccc2C(=O)Nc2ccc(NCCc3csc(N)n3)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GCGR P47871 1/20 0.42
TP53 P04637 4/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
MAPT P10636 2/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
KMT2A Q03164 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HDAC7 Q8WUI4 1/20 0.39
FNTA P49354 1/20 0.38
FNTB P49356 1/20 0.38
KDM1A O60341 2/20 0.38
PLG P00747 1/20 0.38
KLK1 P06870 1/20 0.38
KLK6 Q92876 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6498180 0.94 GCGR (0.50) GCGRTP53MAPTLMNA
SCHEMBL6492802 0.93 POLB (0.47) GCGRTP53MAPTKDM4ELMNA
SCHEMBL6501075 0.92 RAB9A (0.43) TP53NPC1RAB9AMAPTALDH1A1
SCHEMBL6793046 0.90 NPC1 (0.47) TP53NPC1RAB9AMAPTALDH1A1
SCHEMBL6499732 0.90 NPC1 (0.51) GCGRTP53NPC1RAB9AMAPT
SCHEMBL6490142 0.87 POLB (0.43) GCGRTP53NPC1RAB9AMAPT
SCHEMBL6501410 0.86 SMN1; SMN2 (0.60) GCGRTP53NPC1RAB9AMAPT
SCHEMBL6499252 0.86 POLB (0.47) TP53MAPTKDM4ELMNASMN1; SMN2
SCHEMBL6489811 0.85 GCGR (0.51) GCGRTP53NPC1RAB9AMAPT
SCHEMBL6645859 0.85 SMN1; SMN2 (0.40) TP53NPC1RAB9AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 GCGR 1784/4885TP53 3031/4885NPC1 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.